GW Pharmaceutical Gets Closer To Forcing FDA On Cannabis
British biotech company GW Pharmaceuticals announced positive results on its latest Phase 3 clinical trial for its drug Epidiolex. The drug is cannabidiol-based and is used to treat children with Lennox-Gastaut syndrome, a rare form of childhood epilepsy.
GW Pharmaceuticals CEO: Pot-based epilepsy drug trial has taken a ‘huge step’CNBC
GW Pharmaceuticals Is Taking Off as the Cannabis Industry GrowsTheStreet.com
GW Pharmaceuticals (GWPH) Announces Positive Results for Phase 3 Pivotal Trial for Epidiolex, Shares SoarInvestorGuide
all 54 news articles >>
Source: pharmaceutical – Google News
Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd